Authors


Isabelle Lambert

Latest:

Isabelle Lambert, MD: Spike, Spindle Frequency in Hippocampus During NREM Affect Long-Term Memory

Impairment of physiological spindle activity in the hippocampus during NREM sleep by interictal epileptic activities may have negative consequences on long-term memory consolidation.


Annette Langer-Gould, MD, PhD

Latest:

Annette Langer-Gould, MD, PhD: Lowering Postpartum MS Relapse Rates With Breastfeeding

The regional lead in clinical and translational neuroscience at Kaiser Permanente discussed subgroup findings from a study of pregnancy in women with MS which suggested that breastfeeding in the postpartum period can drastically decrease the risk of disease relapse.


Zachary Grinspan, MD, MS

Latest:

Partnering Clinicians With Parents as a Motivator for Pediatric Epilepsy Research: Zachary Grinspan, MD, MS

The pediatric epilepsy specialist at Weill Cornell Medicine in New York City spoke on how meetings such as the 2022 AES Conference bring clinicians together as well as how parents motivate them to advance pediatric epilepsy research. [WATCH TIME: 6 minutes]




Jeffrey L. Cummings, MD, ScD

Latest:

Jeffrey L. Cummings, MD, ScD: Optimal Therapeutic Targets for Addressing Alzheimer Disease

The director emeritus of the Cleveland Clinic Lou Ruvo Center for Brain Health and vice chair of the department of brain health at the University of Nevada Las Vegas spoke about therapies under investigation for the treatment of Alzheimer disease.


Eva Winnebeck, PhD

Latest:

Eva Winnebeck, PhD: Temporal Dynamics of Sleep

The postdoctoral scientist spoke about an actimetry-based method studying the clinical relevance of temporal dynamics of sleep to make the dynamics easily quantifiable in everyday context.


James W. Kupiec, MD

Latest:

Aducanumab's Unlikely Road to the FDA: Is Approval Imminent?

Recent news that the FDA has granted the fastest possible review for Biogen’s Alzheimer disease treatment aducanumab may be indicative of the agency’s increasing confidence in the drug.


Robert Fox, MD

Latest:

Promising Effects of Vidofludimus Calcium by Age and Disability in Progressive MS: Robert J. Fox, MD; Andreas Muehler, MD, MBA

A duo of experts talked about a positive phase 2 trial of vidofludimus calcium, demonstrating reductions in serum neurofilament light levels and potentially slowing brain atrophy in patients with progressive multiple sclerosis. [WATCH TIME: 4 minutes]


Christopher Gottschalk, MD

Latest:

The Changing Landscape of Preventative Migraine Treatments

A panel of expert neurologists shares advice for community neurologists on preventive migraine treatment and exciting therapies to look forward to.


Phyllis C. Zee, MD, PhD

Latest:

Future Improvements in the Management of Narcolepsy

Expert neurologists discuss advancements in the management of narcolepsy including new drug formulations and provide take-home messages for how to improve diagnosis and treatment in the future.


Jeffrey Cummings, MD, ScD

Latest:

Using Prior Success to Improve Alzheimer Trials, Drug Development: Jeffrey Cummings, MD, ScD

The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada, Las Vegas discussed how the momentum gained within the Alzheimer community can springboard success going forward. [WATCH TIME: 4 minutes]


Gill Livingston, MBChB, MD

Latest:

Gill Livingston, MBChB, MD: Challenges of Sleep Difficulties in People Living with Dementia

Livingston spoke to a number of topics in the dementia space, including the challenges clinicians face and her hope for the future.


Raymond S. Turner, MD, PhD

Latest:

Raymond S. Turner, MD, PhD: Safety Results for Nilotinib in Alzheimer

The director of the Memory Disorders Program and professor of neurology at Georgetown University Medical Center detailed the phase 2 study findings of nilotinib in patients with Alzheimer disease.


David Bai, PharmD

Latest:

What You Need to Know About Amantadine for Parkinson Disease

This guide includes everything you need to know about amantadine (Osmolex ER, Osmotica Pharmaceuticals) for the treatment of Parkinson disease and drug-induced extrapyramidal reactions in adults.


Pouya Ghaemmaghami, PhD

Latest:

Pouya Ghaemmaghami, PhD: Predicted Gene Expression and the Association with Sleep Macrostructure

Preliminary results show that the whole genome information can be used to assess the association between predicted gene expression in different parts of the brain and sleep, suggesting where brain genes are expressed matter for variability in sleep.


Eyiyemisi Damisah, MD

Latest:

Eyiyemisi Damisah, MD: Additional Insights Into Cell Death

The assistant professor of neurosurgery at Yale School of Medicine discussed what doors have been opened by a recent study of the cell death process she and colleagues conducted.


Stephen C. Krieger, MD

Latest:

Shared Decision-Making in Multiple Sclerosis Treatment

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, talk about the need for shared decision-making in MS care.


Vineet Punia, MD, MS

Latest:

Treatment Gaps Among Elders With Generalized Epilepsy: Vineet Punia, MD, MS

The neurologist at Cleveland Clinic addressed aspects of care for elders with generalized epilepsy that need to be further researched.



Jessica Fesler, MD, MEd

Latest:

Expanding the Use of Seizure Apps for Epilepsy: Jessica Fesler, MD, MEd

The staff epileptologist at Cleveland Clinic’s Epilepsy Center discussed new untapped ways seizure apps could help patients with epilepsy. [WATCH TIME: 2 minutes]



David Llewellyn, PhD

Latest:

David Llewellyn, PhD: The Impact of Lifestyle Factors on Genetic Risk in Dementia

The associate professor of neuroepidemiology and digital health spoke about the importance of findings from an observational study which showed that adherence to a healthy lifestyle can offset the genetic risk for dementia.


David Leppert, MD

Latest:

David Leppert, MD: Building a Foundation for Neurofilament Light

The therapeutic head of neuroinflammation and pain at Novartis spoke about his desire to work to a point where physicians can use NfL to monitor disease activity, make therapeutic decisions, and give perspective to patients.


Peter J. McAllister, MD, FAAN

Latest:

Introducing DaxibotulinumtoxinA-Ianm as a Treatment Option for Cervical Dystonia: Peter J. McAllister, MD, FAAN

The chief medical officer of New England Center for Neurology and Headache talked about trends observed in the clinical practice with Daxxify, a long-acting botulinum toxin for patients with cervical dystonia. [WATCH TIME: 5 minutes]


Will Pass, DVM

Latest:

Sigma-1 Agonists Offer Combination Approach to Dementia Symptoms

Research from the past decade suggests that sigma-1 receptors and their encoding gene, SIGMAR1, together act as a therapeutic target for patients with dementia.


Ian Miller, MD

Latest:

Ian Miller, MD: Adapting AAV Gene Therapy for SCN1A-Positive Epilepsy

The medical director of the Comprehensive Epilepsy Clinic at Nicklaus Children’s Hospital discusses his early stage gene therapy trial for Dravet syndrome.


James Stankiewicz, MD

Latest:

Early High-Efficacy Treatment

James Stankiewicz, MD, provides an overview of the burden of multiple sclerosis and discusses early, high-efficacy treatment of the disease.


Peter Calabresi, MD

Latest:

Peter Calabresi, MD: Utilizing A Uniform Biomarker Assay

For the director of the Johns Hopkins Multiple Sclerosis Center, a biomarker is perhaps only as useful as the clinician community’s ability to read out its measurements.


Robert S. Fisher, MD, PhD

Latest:

Robert S. Fisher, MD, PhD: Exploring Unanswered Questions in Epilepsy

The Director of the Stanford Epilepsy Center discussed the work that’s left to be done in the field of epilepsy.

© 2024 MJH Life Sciences

All rights reserved.